Innovations in Radiation Therapy Planning Unveiled by RaySearch

Innovative Integration of Technologies for Cancer Treatment

At a recent conference, RaySearch Laboratories AB and Vision RT proudly announced a significant advancement in their partnership. This development centers around the full integration of MapRT with the RayStation treatment planning system. The synergy between these technologies allows practitioners unparalleled access to the MapRT clearance map, which plays a vital role in guiding treatment planning by ensuring safe beam trajectories that avoid potential collisions between the treatment unit, patient, and couch.

Enhancing Treatment Accuracy with MapRT

During the CT simulation process, the MapRT technology harnesses advanced camera systems that capture the patient's surface and any immobilization devices utilized. This software then processes the gathered data in conjunction with models of the treatment couch and machine, producing a clearance map that optimizes gantry and couch angles during treatment planning. By utilizing this crucial information within RayStation, clinicians can refine beam options, optimize treatment plans and minimize the necessity for dry runs, significantly benefitting patient outcomes.

Improved Outcomes from Non-Coplanar Treatments

Recent research highlights the clinical advantages that arise from non-coplanar treatment plans. Such approaches have shown improvements in treating various cancers, including lung, breast, head, neck cancers, lymphoma, and high-grade gliomas. The integration of MapRT into the RayStation system makes it easier to explore these techniques, reducing the likelihood of complications associated with traditional treatment methods and enhancing organ-at-risk dose sparing.

Expert Insights on New Developments

Helen Convery, a Senior Dosimetrist involved in the integration process, remarked on the valuable role MapRT has played in collision detection and optimizing plan angles within their operational workflows. The successful use of this technology in clinical settings since 2022 underscores its importance in promoting efficient treatment planning.

Vision RT's Perspective on the Collaboration

Vision RT's VP of Marketing, Thomas Carter, expressed enthusiasm regarding the changes in clinical planning techniques emerging from this collaboration. As clinics embrace the new beam options enabled by MapRT, there is a shift towards more efficient workflows that promise to reduce errors and enhance predictability in treatment outcomes. These advancements pave the way for automatic collision-free planning, taking radiation therapy to the next level.

RaySearch's Commitment to Patient-Centric Solutions

Björn Hårdemark, Deputy CEO of RaySearch, emphasized the integral role of surface scanning in radiation therapy. The combination of MapRT with RayStation provides clinicians with valuable data during treatment planning, allowing for enhanced creativity in beam configurations while safely maintaining the patient’s clearance. This innovation illustrates the benefits of collaboration between leading technology vendors in radiation therapy.

Future of Radiation Therapy with MapRT

The MapRT technology has received CE marking for clinical use across the EU and the UK, while a compatible version is set for distribution in the USA, with additional regulatory approvals pending. The trajectory of this integration points towards a more refined process in delivering radiation therapy, ensuring both efficacy and patient safety.

About Vision RT

Vision RT, a pioneer in Surface Guided Radiation Therapy (SGRT), focuses on leveraging camera systems that track surface data across various stages of the radiotherapy workflow—spanning simulation, planning, treatment, and dose visualization. The company is dedicated to enhancing the overall experience of radiation therapy for both patients and clinicians alike.

About RaySearch Laboratories

RaySearch Laboratories AB specializes in developing cutting-edge software solutions designed to improve cancer treatment. With the RayStation treatment planning system at the forefront, alongside innovations like RayCare, RayIntelligence, and RayCommand, RaySearch's offerings empower over 1,100 clinics across 47 countries.

For More Information

Interested individuals can reach out to Johan Löf, CEO of RaySearch Laboratories AB, at +46 (0) 8 510 530 00 for inquiries about the latest advancements in treatment planning technology.

Frequently Asked Questions

What is the significance of the RayStation and MapRT integration?

This integration allows clinicians to optimize treatment planning by providing real-time clearance maps that improve safety and efficacy in radiation therapy.

How does MapRT enhance treatment planning?

MapRT captures comprehensive surface data during CT simulations, allowing treatment teams to select optimal beam angles and configurations that avoid collisions.

What types of cancers benefit from non-coplanar treatment plans?

Research shows that non-coplanar treatment plans can be particularly effective in treating lung, breast, and head-and-neck cancers, among others.

What future developments can we expect from RaySearch and Vision RT?

Both companies are committed to advancing the integration of technologies that further enhance the safety and effectiveness of radiation therapy.

What is Vision RT's core mission?

Vision RT strives to improve the precision, efficiency, and comfort of radiation therapy through innovative surface tracking technologies.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.